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Background
A I D S - P C N S Li sar a r eE B V - a s s ociated B-cell neoplasm
that continues to carry a poor prognosis, even in the
highly active antiretroviral therapy (HAART) era. We
hypothesized that overall survival (OS) is affected by
prior diagnosis of central nervous system (CNS) infec-
tions as well as treatment approaches to both HIV and
AIDS-PCNSL. We evaluated risk factors and temporal
trends for OS in patients with AIDS-PCNSL.
Methods
Adults with AIDS-PCNSL were identified through a
computer linkage that matched AIDS case diagnosed
between 1990-2000 from the San Francisco adult AIDS
case registry with the California Cancer Registry (1985-
2002), with mortality follow-up through 12/31/2007.
Patients with non-B-cell histology or history of systemic
non-Hodkgin lymphoma diagnosed within 2 years prior
to AIDS-PCNSL diagnosis were excluded. Prognostic fac-
tors evaluated include: diagnosis of CNS infection prior
to AIDS-PCNSL, diagnosis of other common opportunis-
tic infection (OI) prior to AIDS-PCNSL (pneumocystis
pneumonia [PCP] or mycobacterium avium complex
[MAI]), pathologic versus clinical diagnosis, receipt of
cancer therapy, HAART prescribed prior to or within 30
days of AIDS-PCNSL diagnosis, and year of diagnosis
(1990-1995, 1996-1998, 1999-2002). Survival analyses
employed Kaplan-Meier methodology.
Results
A total of 207 patients were identified, 96% male and 4%
female. Median age 39 (IQR 35-46), 68% white, 21%
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(IQR 6-53). HIV risk group: 79% MSM, 8% IDU, 9%
MSM/IDU. CNS infections prior to AIDS-PCNSL: toxo-
plasmosis 8%, cryptococcus 9%, histoplasmosis 1%,
extrapulmonary tuberculosis 1%. Treatment category:
none 42%, radiation only 52%, chemotherapy 6% (5/13
chemotherapy only, 6/13 chemotherapy and radiation,
2/13 chemotherapy and immunotherapy). Risk factors
for OS included prior CNS infection (p<0.0001),
HAART (p=0.0023), AIDS-PCNSL treatment (p<0.0001),
and calendar period of AIDS-PCNSL diagnosis (0.001),
but not prior PCP or MAC (p= 0.23). (Figures 1 A-D.)
OS was improved by HAART across treatment groups
(p<0.0001).
Conclusions
Prior diagnosis of CNS infection, HAART, and cancer
treatment are strong predictors of OS. OS improved
over time in these patients. Earlier diagnosis of AIDS-
PCNSL and/or CNS infection, treatment of CNS infec-
tions, and cancer treatment that includes HAART and
concomitant chemotherapy may increase AIDS-PCNSL
survival. Prospective evaluation of curative-intent che-
motherapy-based approaches to AIDS-PCNSL is
urgently needed. Additional analyses are ongoing.
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